Michael Janusz Koss

Michael Janusz Koss

Auto-generated profile, based on publicly available information

Michael Janusz Koss

Augenzentrum Nymphenburger Höfe, 80335 Munich, Germany

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

14 May 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MKMichael Janusz Koss
Michael Janusz Koss
JHJanosch Hoffmann
Janosch Hoffmann
NNNauke Nguyen
Nauke Nguyen
MPMarcel Pfister
Marcel Pfister
HMHarald Mischak
Harald Mischak
JSJustyna Siwy
Justyna Siwy
There is absence of specific biomarkers and an incomplete understanding of the pathophysiology of exudative age-related macular degeneration (AMD). Eighty-eight vitreous samples (73 from patients with treatment naïve AMD and 15 control samples from patients with idiopathic floaters) were analyzed with capillary electrophoresis coupled to mass spectrometry in this retrospective case series to define potential candidate protein markers of AMD. Nineteen proteins were found to be upregulated in vitreous of AMD patients. Most of the proteins were plasma derived and involved in biological (ion) transport, acute phase inflammatory reaction, and blood coagulation. A number of proteins have not been previously associated to AMD including alpha-1-antitrypsin, fibrinogen alpha chain and prostaglandin H2-D isomerase. Alpha-1-antitrypsin was validated in vitreous of an independent set of AMD patients using Western blot analysis. Further systems biology analysis of the data indicated that the observed proteomic changes may reflect upregulation of immune response and complement activity. Proteome analysis of vitreous samples from patients with AMD, which underwent an intravitreal combination therapy including a core vitrectomy, steroids and bevacizumab, revealed apparent AMD-specific proteomic changes. The identified AMD-associated proteins provide some insight into the pathophysiological changes associated with AMD.

8 November 2011 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
MKMichael J Koss
Michael J Koss
MPMarcel Pfister
Marcel Pfister
FRFlorian Rothweiler
Florian Rothweiler
MMMartin Michaelis
Martin Michaelis
JCJindrich Cinatl
Jindrich Cinatl
FKFrank H Koch
Frank H Koch

22 June 2016 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
MKMichael J. Koss
Michael J. Koss
PFPaulo Falabella
Paulo Falabella
FSFrancisco R. Stefanini
Francisco R. Stefanini
MPMarcel Pfister
Marcel Pfister
BTBiju B. Thomas
Biju B. Thomas
MHMark S. Humayun
Mark S. Humayun

30 October 2017 in International Journal of Retina and Vitreous
Verified
Journal Article
Open access
PDF file
RFRodrigo A. Brant Fernandes
Rodrigo A. Brant Fernandes
FSFrancisco R. Stefanini
Francisco R. Stefanini
PFPaulo Falabella
Paulo Falabella
MKMichael J. Koss
Michael J. Koss
TWTrent Wells
Trent Wells
MHMark Humayun
Mark Humayun
Subretinal cell transplantation is a challenging surgical maneuver. This paper describes the preliminary findings of a new tissue injector for subretinal implantation of an ultrathin non-absorbable substrate seeded with human embryonic stem cell-derived retinal pigment epithelium (hESC-RPE). Ultrathin Parylene-C substrates measuring 3.5 mm × 6.0 mm seeded with hESC-RPE (implant referred to as CPCB-RPE1) were implanted into the subretinal space of 12 Yucatan minipigs. Animals were euthanized immediately after the procedure and underwent spectral domain optical coherence tomography (SD-OCT) and histological analysis to assess the subretinal placement of the implant. Evaluation of the hESC-RPE cells seeded on the substrate was carried out before and after implantation using standard cell counting techniques. The tissue injector delivered the CPCB-RPE1 implant through a 1.5 mm sclerotomy and a 1.0–1.5 mm retinectomy. SD-OCT scans and histological examination revealed that substrates were precisely placed in the subretinal space, and that the hESC-RPE cell monolayer continued to cover the surface of the substrate after the surgical procedure. This innovative tissue injector was able to efficiently deliver the implant in the subretinal space of Yucatan minipigs, preventing significant hESC-RPE cell loss, minimizing tissue trauma, surgical complications and postoperative inflammation.

11 May 2020 in Translational Vision Science & Technology
Verified
Journal Article
Open access
PDF file
JFJulian Friedrich
Julian Friedrich
DSDavid H Steel
David H Steel
RSReinier O. Schlingemann
Reinier O. Schlingemann
MKMichael J. Koss
Michael J. Koss
HHHans-Peter Hammes
Hans-Peter Hammes
IKIngeborg Klaassen
Ingeborg Klaassen
Purpose: microRNAs (miRNAs) mediate the pathological mechanisms of diabetic retinopathy. In this study, we compared miRNA expression profiles in the vitreous between patients with proliferative diabetic retinopathy (PDR) and patients with a macular hole as non-diabetic controls, and between PDR patients treated with anti-vascular endothelial growth factor (VEGF) therapy and untreated PDR patients. Methods: Vitreous samples of non-diabetic and PDR patients were screened for miRNAs with quantitative polymerase chain reaction (qPCR) panels. miRNA candidates were validated in vitreous samples of a second, independent cohort. In addition, the effect of anti-VEGF therapy was investigated in the vitreous of a third study population consisting of PDR patients who had not received anti-VEGF therapy and PDR patients who had received preoperative anti-VEGF therapy. Results: During screening, seven miRNAs were found to be significantly higher in the vitreous of PDR patients, whereas two miRNAs were found to be significantly lower compared with non-diabetic controls. Validating the expression of these miRNAs in a second cohort resulted in the identification of six miRNAs that were expressed at significantly higher rates in the vitreous of PDR patients: hsa-miR-20a-5p, hsa-miR-23b-3p, hsa-miR-142-3p, hsa-miR-185-5p, hsa-miR-326, and hsa-miR-362-5p. Among these six miRNAs, hsa-miR-23b-3p levels were lower in the anti-VEGF-treated group of PDR patients compared with untreated PDR patients. Conclusions: In this study, we identified six miRNAs that are expressed more highly in PDR patients and one miRNA that is expressed at a lower levels in anti-VEGF-treated PDR patients. Translational Relevance: miRNAs identified in the vitreous of PDR patients may improve our understanding of the mechanisms leading to PDR.